Y-mAbs Therapeutics (YMAB) Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Do institutionals & insiders believe in YMAB or TVTX?

70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 19.7% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 4.1% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has higher valuation and earnings, YMAB or TVTX?

Y-mAbs Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$87.68M	4.42	-$29.67M	-$0.50	-17.05
Travere Therapeutics	$233.18M	7.17	-$321.55M	-$2.04	-9.19

Does the media prefer YMAB or TVTX?

In the previous week, Travere Therapeutics had 8 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 10 mentions for Travere Therapeutics and 2 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.12 beat Travere Therapeutics' score of 1.02 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Y-mAbs Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, YMAB or TVTX?

Y-mAbs Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Is YMAB or TVTX more profitable?

Y-mAbs Therapeutics has a net margin of -26.03% compared to Travere Therapeutics' net margin of -50.64%. Y-mAbs Therapeutics' return on equity of -24.60% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-26.03%	-24.60%	-18.89%
Travere Therapeutics	-50.64%	-717.68%	-30.69%

Do analysts prefer YMAB or TVTX?

Y-mAbs Therapeutics currently has a consensus price target of $9.62, indicating a potential upside of 12.87%. Travere Therapeutics has a consensus price target of $32.21, indicating a potential upside of 71.81%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than Y-mAbs Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	2 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Travere Therapeutics	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

Y-mAbs Therapeutics and Travere Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.